 Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2 HALT-D study evaluating crofelemer for prevention and prophylaxis of diarrhea in breast cancer patients as a poster for December 2021 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA ACCESSWIRE October 7, 2021 Jaguar Health, Inc. NASDAQ:JAGX provided updates today regarding ongoing research and development related to the companys crofelemer drug product candidates, and also announced that Dragon SPAC S.p.A. and Napo EU S.p.A. 